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Overexpression of tumor associated antigens (TAA) such
as carbonic anhydrase 9 (CA9), HER2/neu and high mole-
cular weight melanoma associated antigen (HMW-MAA)
is associated with aggressive high-grade tumors leading to
disease progression and reduced survival. CA9 is a cell
surface enzyme that catalyzes the reversible hydration of
carbon dioxide to bicarbonate and is overexpressed in
response to tumor hypoxia in many common tumor types.
CA9 plays a critical role in hypoxia-associated tumor acido-
sis, which plays an important role in tumor progression and
chemoresistance in various types of cancer. Current
HER2/neu-directed therapies confer limited clinical
benefits and most patients experience progressive disease
indicating that additional therapeutic strategies targeting
HER2/neu could have potential. HMW-MAA is reported
to be a TAA as well as an angiogenesis associated protein,
as it is expressed at high levels by activated pericytes and
pericytes in tumor angiogenic vasculature that are asso-
ciated with neovascularization in vivo. We hypothesized
that an Lm-LLO immunotherapy, using attenuated
Listeria moncytogenes (Lm)-LLO as the vector capable of
delivering multiple antigens would likely have a synergistic
effect on decreasing tumor growth by targeting indepen-
dent mechanisms that support tumor growth. We created
two bivalent Lm-LLO immunotherapies expressing two
antigens such as HER2/HMW-MAA or HER2/CA9.
These bivalent Lm-LLO immunotherapies efficiently
secreted two antigens, grew intracellularly and escaped the
phagolysosome, supporting that recombinant bacteria
retained their ability to deliver antigen successfully in an
antigen presenting cell. Preliminary antitumor therapeutic
studies in the treatment of mice bearing established
tumors expressing HER2 demonstrate that both of these
bivalent Lm-LLO immunotherapies show an improvement
in the reduction of tumor growth when compared to
monovalent Lm-LLO immunotherapies. We will present
data on the therapeutic efficacy of two bivalent Lm-LLO
immunotherapies and provide evidence on the mechan-
isms likely responsible for the observed anti-tumor effects.
Currently Lm-LLO immunotherapies are being evaluated
in Phase II clinical trials for HPV-associated malignancies
such as cervical, head and neck, and anal cancers.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P63
Cite this article as: Wallecha and Molli: Lm-LLO immunotherapies
targeting multiple antigens and their impact on different mechanisms
in the tumor microenvironment. Journal for ImmunoTherapy of Cancer
2014 2(Suppl 3):P63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Advaxis, Inc, Princeton, NJ, USA
Wallecha and Molli Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P63
http://www.immunotherapyofcancer.org/content/2/S3/P63
© 2014 Wallecha and Molli; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
